These observations indicate that host could contribute to relapse after S-1 adjuvant chemotherapy in addition to tumor cell-intrinsic 5FU resistance or immunosuppression mechanisms (i.e., activation of PAK–MEK1 pathways or PD-L1 expression). The gene discussed is MAP2K1; the disease is neoplasm.